129 related articles for article (PubMed ID: 26097902)
1. Faldaprevir for the treatment of hepatitis C.
Campagna D; Demma S
Drugs Today (Barc); 2015 May; 51(5):289-301. PubMed ID: 26097902
[TBL] [Abstract][Full Text] [Related]
2. Faldaprevir for the treatment of genotype-1 hepatitis C virus.
Agarwal K; Barnabas A
Expert Rev Gastroenterol Hepatol; 2015 Mar; 9(3):277-88. PubMed ID: 25633983
[TBL] [Abstract][Full Text] [Related]
3. Faldaprevir for the treatment of hepatitis C.
Kanda T; Yokosuka O; Omata M
Int J Mol Sci; 2015 Mar; 16(3):4985-96. PubMed ID: 25749475
[TBL] [Abstract][Full Text] [Related]
4. Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.
Jensen DM; Asselah T; Dieterich D; Foster GR; Sulkowski MS; Zeuzem S; Mantry P; Yoshida EM; Moreno C; Ouzan D; Wright M; Morano LE; Buynak R; Bourlière M; Hassanein T; Nishiguchi S; Kao JH; Omata M; Paik SW; Wong DK; Tam E; Kaita K; Feinman SV; Stern JO; Scherer J; Quinson AM; Voss F; Gallivan JP; Böcher WO; Ferenci P
Ann Hepatol; 2016; 15(3):333-49. PubMed ID: 27049487
[TBL] [Abstract][Full Text] [Related]
5. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection.
Manns MP; Bourlière M; Benhamou Y; Pol S; Bonacini M; Trepo C; Wright D; Berg T; Calleja JL; White PW; Stern JO; Steinmann G; Yong CL; Kukolj G; Scherer J; Boecher WO
J Hepatol; 2011 Jun; 54(6):1114-22. PubMed ID: 21145839
[TBL] [Abstract][Full Text] [Related]
6. Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study.
Berger KL; Lagacé L; Triki I; Cartier M; Marquis M; Lawetz C; Bethell R; Scherer J; Kukolj G
Antimicrob Agents Chemother; 2013 Oct; 57(10):4928-36. PubMed ID: 23877706
[TBL] [Abstract][Full Text] [Related]
7. Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results.
Zeuzem S; Asselah T; Angus P; Zarski JP; Larrey D; Müllhaupt B; Gane E; Schuchmann M; Lohse AW; Pol S; Bronowicki JP; Roberts S; Arasteh K; Zoulim F; Heim M; Stern JO; Nehmiz G; Kukolj G; Böcher WO; Mensa FJ
Antivir Ther; 2013; 18(8):1015-9. PubMed ID: 23558093
[TBL] [Abstract][Full Text] [Related]
8. Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
Dieterich D; Nelson M; Soriano V; Arastéh K; Guardiola JM; Rockstroh JK; Bhagani S; Laguno M; Tural C; Ingiliz P; Jain MK; Stern JO; Manero M; Vinisko R; Kort J;
AIDS; 2015 Mar; 29(5):571-81. PubMed ID: 25710287
[TBL] [Abstract][Full Text] [Related]
9. Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
Berger KL; Sarrazin C; Nelson DR; Scherer J; Sha N; Marquis M; Côté-Martin A; Vinisko R; Stern JO; Mensa FJ; Kukolj G
PLoS One; 2016; 11(8):e0160668. PubMed ID: 27494410
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
Gentile I; Carleo MA; Borgia F; Castaldo G; Borgia G
Expert Opin Investig Drugs; 2010 Jan; 19(1):151-9. PubMed ID: 20001560
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
[TBL] [Abstract][Full Text] [Related]
12. STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.
Ferenci P; Asselah T; Foster GR; Zeuzem S; Sarrazin C; Moreno C; Ouzan D; Maevskaya M; Calinas F; Morano LE; Crespo J; Dufour JF; Bourlière M; Agarwal K; Forton D; Schuchmann M; Zehnter E; Nishiguchi S; Omata M; Kukolj G; Datsenko Y; Garcia M; Scherer J; Quinson AM; Stern JO;
J Hepatol; 2015 Jun; 62(6):1246-55. PubMed ID: 25559324
[TBL] [Abstract][Full Text] [Related]
13. Telaprevir: hope on the horizon, getting closer.
Weisberg IS; Jacobson IM
Clin Liver Dis; 2009 Aug; 13(3):441-52. PubMed ID: 19628160
[TBL] [Abstract][Full Text] [Related]
14. Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study.
Zeuzem S; Dufour JF; Buti M; Soriano V; Buynak RJ; Mantry P; Taunk J; Stern JO; Vinisko R; Gallivan JP; Böcher W; Mensa FJ;
Liver Int; 2015 Feb; 35(2):417-21. PubMed ID: 25263751
[TBL] [Abstract][Full Text] [Related]
15. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.
Lawitz E; Sulkowski M; Jacobson I; Kraft WK; Maliakkal B; Al-Ibrahim M; Gordon SC; Kwo P; Rockstroh JK; Panorchan P; Miller M; Caro L; Barnard R; Hwang PM; Gress J; Quirk E; Mobashery N
Antiviral Res; 2013 Sep; 99(3):214-20. PubMed ID: 23747481
[TBL] [Abstract][Full Text] [Related]
16. Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.
Zeuzem S; Mantry P; Soriano V; Buynak RJ; Dufour JF; Pockros PJ; Wright D; Angus P; Buti M; Stern JO; Kadus W; Vinisko R; Böcher W; Mensa FJ
Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):923-6. PubMed ID: 27140229
[TBL] [Abstract][Full Text] [Related]
17. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
Pascale A; Serfaty L
J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
[TBL] [Abstract][Full Text] [Related]
18. Anemia management in patients with chronic viral hepatitis C.
Hynicka LM; Heil EL
Ann Pharmacother; 2013 Feb; 47(2):228-36. PubMed ID: 23386076
[TBL] [Abstract][Full Text] [Related]
19. Second-wave protease inhibitors: choosing an heir.
Ciesek S; von Hahn T; Manns MP
Clin Liver Dis; 2011 Aug; 15(3):597-609. PubMed ID: 21867939
[TBL] [Abstract][Full Text] [Related]
20. Faldaprevir and deleobuvir for HCV genotype 1 infection.
Zeuzem S; Soriano V; Asselah T; Bronowicki JP; Lohse AW; Müllhaupt B; Schuchmann M; Bourlière M; Buti M; Roberts SK; Gane EJ; Stern JO; Vinisko R; Kukolj G; Gallivan JP; Böcher WO; Mensa FJ
N Engl J Med; 2013 Aug; 369(7):630-9. PubMed ID: 23944300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
